SEC Filing Summary: BioSig Technologies, Inc. (Form 8-K)
Business Context and Reporting Period
This Current Report on Form 8-K was filed by BioSig Technologies, Inc. on May 29, 2015, covering events occurring on May 20, 2015, and May 22, 2015. The filing addresses corporate governance changes, specifically the amendment of the company's equity incentive plan and changes to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses on corporate actions rather than financial performance results.
Material Changes
- Equity Incentive Plan Amendment: The Board approved an amendment to the 2012 Equity Incentive Plan, which was subsequently approved by stockholders on May 22, 2015. The amendment revises the definition of "Fair Market Value" for stock awards to the arithmetic mean of the sales price for the ten trading days immediately preceding the date of determination, applicable if the stock is listed on an established exchange or national market system.
- Board Composition Changes: Jonathan Steinhouse resigned from the Board, effective May 22, 2015. David Weild was appointed to the Board on the same date to serve until the 2015 annual meeting of stockholders.
- Compensatory Arrangements: In connection with his appointment, David Weild was granted stock options to purchase 300,000 shares of Common Stock in total (250,000 shares with 50% immediate vesting and 50% vesting after one year; 50,000 shares vesting monthly over 12 months).
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or management commentary regarding future business performance. No specific risks or contingencies were disclosed in this report other than the standard vesting conditions attached to the new director's stock options.
Key Facts for Investor Verification
- Verify the impact of the new "Fair Market Value" definition on future equity compensation costs and potential dilution.
- Confirm the total number of shares authorized under the amended 2012 Equity Incentive Plan to assess remaining capacity for future grants.
- Review the full text of Exhibit 99.1 for complete terms of the Equity Incentive Plan Amendment.
- Monitor the vesting schedule of the 300,000 shares granted to new director David Weild.